RecruitingNCT06795893

The Anifrolumab PRIM Program

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AstraZeneca
Principal Investigator
Syd Philips
PPD Miami, US
Intervention
Anifrolumab(drug)
Enrollment
240 enrolled
Eligibility
FEMALE
Timeline
20252031

Study locations (1)

Collaborators

PPD Development, LP

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06795893 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials